Authors

• Alwin D. R. Huitema (ORCID: https://orcid.org/0000-0003-1939-4639)
• Rob ter Heine (ORCID: https://orcid.org/0000-0003-2185-8201)
• David Marinus Burger (ORCID: https://orcid.org/0000-0001-7279-2818)
• Alfons A den Broeder (ORCID: https://orcid.org/0000-0002-9012-4079)
• Nielka P. van Erp (ORCID: https://orcid.org/0000-0003-1553-178X)
• Joanneke K. Overbeek (ORCID: https://orcid.org/0000-0002-8802-4124)
• Stijn L.W. Koolen (ORCID: https://orcid.org/0000-0002-0973-7530)

Institutions

• Radboud University Nijmegen (NL)
• Utrecht University (NL)
• Erasmus MC (NL)
• Radboud University Medical Center (NL)
• The Netherlands Cancer Institute (NL)
• University Medical Center Utrecht (NL)
• Radboud Institute for Molecular Life Sciences (NL)
• Oncode Institute (NL)
• Princess Máxima Center (NL)
• Sint Maartenskliniek (NL)
• Erasmus MC Cancer Institute (NL)

Publication Details

Journal

Clinical Pharmacokinetics

Published

2025-02-05

DOI

https://doi.org/10.1007/s40262-025-01480-w

Primary Topic

PARP inhibition in cancer therapy

Type

article

Field-Weighted Citation Impact

0.00

Funders

• ZonMw